Search

EHA reaffirms commitment to hematology's future with new brand identity

The European Hematology Association (EHA) is thrilled to announce the launch of our new brand identity. This includes a refreshed logo, updated color palette, and a new slogan, marking a significant milestone in our journey.

Read more

ABT-199: Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL.

Chronic Lymphocytic Leukaemia (CLL) is the most common leukemia in adults in the Western world and is diagnosed in approximately 5 persons per 100,000 population per year.

Read more

ATMPs and CAR-T: the uptake challenge

Advanced therapy medicinal products (ATMPs) are a game changer for improving the life of patients with severe to life-threatening diseases. In hematology, for instance, CAR T cell therapy has shown promising results in tackling different blood cancers.

Read more

European Hematologists will discuss breakthroughs in blood disorders in Milan, Italy - June 12-15, 2014

About the EHA Annual Congress

Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases of blood and their treatments.

Read more

EHA Statement: Our sustained solidarity with the hematology community in Ukraine

Friday, February 24 marks one year of war. The European Hematology Association (EHA) stands in solidarity with our colleagues and friends in Ukraine.

Read more

Turning thoughts into reality

Turning thoughts into reality
By Dr Adi Zoref (@ZorefAdi)

I am an Israeli physician, trained in internal medicine. During my residency rotation in hematology at Meir Medical Center, I met a patient who changed my life.

Read more